

(51) International Patent Classification:
C07K 14/605 (2006.01)(21) International Application Number:
PCT/EP2014/077240(22) International Filing Date:
10 December 2014 (10.12.2014)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/915,662 13 December 2013 (13.12.2013) US(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Mil-
stein Building, Granta Park, Cambridge Cambridgeshire
CB21 6GH (GB).(72) Inventors: **REVELL, Jefferson**; c/o MedImmune Lim-
ited, Milstein Building, Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB). **BEDNAREK, Maria**; c/o
MedImmune Limited, Milstein Building, Granta Park,
Cambridge Cambridgeshire CB21 6GH (GB).(74) Agent: **TTOFI, Evangelia**; Milstein Building, Granta
Park, Cambridge Cambridgeshire CB21 6GH (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).**Published:**— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: PROTEASE RESISTANT PEPTIDES

FIG. 1



(57) Abstract: The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. Incorporation of alpha-methyl-functionalized amino acids directly into the main chain during standard peptide synthesis via the methodologies described herein has been determined to produce protease-resistant peptides.